Cargando…

Predictors of disability worsening in clinically isolated syndrome

OBJECTIVE: To assess demographic, clinical, magnetic resonance imaging, and treatment exposure predictors of time to 3 or 12-month confirmed disability worsening in clinically isolated syndrome (CIS) and early multiple sclerosis (MS). METHODS: We utilized the MSBase Incident Study (MSBasis), a prosp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jokubaitis, Vilija G, Spelman, Tim, Kalincik, Tomas, Izquierdo, Guillermo, Grand'Maison, François, Duquette, Pierre, Girard, Marc, Lugaresi, Alessandra, Grammond, Pierre, Hupperts, Raymond, Cabrera-Gomez, José, Oreja-Guevara, Celia, Boz, Cavit, Giuliani, Giorgio, Fernández-Bolaños, Ricardo, Iuliano, Gerardo, Lechner-Scott, Jeannette, Verheul, Freek, van Pesch, Vincent, Petkovska-Boskova, Tatjana, Fiol, Marcela, Moore, Fraser, Cristiano, Edgardo, Alroughani, Raed, Bergamaschi, Roberto, Barnett, Michael, Slee, Mark, Vella, Norbert, Herbert, Joseph, Shaw, Cameron, Saladino, Maria Laura, Amato, Maria Pia, Liew, Danny, Paolicelli, Damiano, Butzkueven, Helmut, Trojano, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435703/ https://www.ncbi.nlm.nih.gov/pubmed/26000321 http://dx.doi.org/10.1002/acn3.187

Ejemplares similares

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
por: Spelman, Timothy, et al.
Publicado: (2021)

Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis
por: Trojano, Maria, et al.
Publicado: (2012)

Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome
por: Meyniel, Claire, et al.
Publicado: (2012)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry
por: Rojas, Juan Ignacio, et al.
Publicado: (2015)

Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS
por: Ribbons, Karen Ann, et al.
Publicado: (2015)

Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis
por: Kalincik, Tomas, et al.
Publicado: (2013)

The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform
por: Jokubaitis, Vilija G., et al.
Publicado: (2013)

Confirmed disability progression as a marker of permanent disability in multiple sclerosis
por: Sharmin, Sifat, et al.
Publicado: (2022)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Parity is associated with long-term differences in DNA methylation at genes related to neural plasticity in multiple sclerosis
por: Campagna, Maria Pia, et al.
Publicado: (2023)

The MSBase pregnancy, neonatal outcomes, and women’s health registry
por: Jokubaitis, Vilija G., et al.
Publicado: (2021)

Epigenome-wide association studies: current knowledge, strategies and recommendations
por: Campagna, Maria Pia, et al.
Publicado: (2021)

Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies
por: Bridge, Francesca, et al.
Publicado: (2023)

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study
por: Barnett, Michael, et al.
Publicado: (2021)

Whole-blood methylation signatures are associated with and accurately classify multiple sclerosis disease severity
por: Campagna, Maria Pia, et al.
Publicado: (2022)

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
por: Paolicelli, Damiano, et al.
Publicado: (2009)

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study
por: Kappos, Ludwig, et al.
Publicado: (2017)

MS, pregnancy and COVID-19
por: Yam, Charmaine, et al.
Publicado: (2020)

Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis
por: Maltby, Vicki, et al.
Publicado: (2023)

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
por: Sharmin, Sifat, et al.
Publicado: (2023)

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2020)

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis
por: Xavier, Alexandre, et al.
Publicado: (2023)

A case report of late‐onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review
por: Parisi, Mosè, et al.
Publicado: (2020)

Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate
por: Bollo, Luca, et al.
Publicado: (2022)

Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study
por: Jacques, F., et al.
Publicado: (2012)

Treatment of Women with Multiple Sclerosis Planning Pregnancy
por: Krysko, Kristen M., et al.
Publicado: (2021)

DNA Methylation Signatures of Multiple Sclerosis Occur Independently of Known Genetic Risk and Are Primarily Attributed to B Cells and Monocytes
por: Xavier, Alexandre, et al.
Publicado: (2023)

Determinants of disability development in patients with multiple sclerosis
por: Kara, Fatma, et al.
Publicado: (2021)

Enriching health-professional programs in global health: Development and implementation of an interdisciplinary and integrated approach
por: Valois, Carol, et al.
Publicado: (2017)

Association between occupational exposures and sarcoma incidence and mortality: systematic review and meta-analysis
por: Edwards, D., et al.
Publicado: (2021)

Endogenously regulated Dab2 worsens inflammatory injury in experimental autoimmune encephalomyelitis
por: Jokubaitis, Vilija G, et al.
Publicado: (2013)

Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years
por: Guerra, Tommaso, et al.
Publicado: (2021)

Responsabilidad social empresaria : comunicación y cooperación en el área de la RSE /
por: Hupperts, Pierre
Publicado: (2005)

Leukemia Inhibitory Factor Protects Axons in Experimental Autoimmune Encephalomyelitis via an Oligodendrocyte-Independent Mechanism
por: Gresle, Melissa M., et al.
Publicado: (2012)

Sertraline versus amitriptyline in the prophylactic therapy of non-depressed chronic tension-type headache patients
por: Boz, Cavit, et al.
Publicado: (2003)

The feasibility, reliability and concurrent validity of the MSReactor computerized cognitive screening tool in multiple sclerosis
por: Merlo, Daniel, et al.
Publicado: (2019)

Multiple sclerosis risk variants regulate gene expression in innate and adaptive immune cells
por: Gresle, Melissa M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_06lg3o24pdnh75s6n7h5h559bn